An evaluation of glasdegib for the treatment of acute myelogenous leukemia

References

• Visser O, Trama A, Maynadié M, et al. RARECARE Working Group. Incidence, survival and prevalence of myeloid malignancies in Europe. Eur J Cancer. 2012;48:3257–3266.
   PubMed Web of Science ®Google Scholar
• Howlader N, Noone AM, Krapcho M, et al. SEER cancer statistics review, 1975–2013. Bethesda (MD): National Cancer Institute; 2016. http://seer.cancer.gov/csr/1975_2013. based on November 2015 SEER data submission, April 2016.
   Google Scholar
• Döhner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373:1136–1152.
   PubMed Web of Science ®Google Scholar
• Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424–447.
   PubMed Web of Science ®Google Scholar
• Stone RM, Mandrekar SJ, Sanford BL, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with FLT3 mutation. N Engl J Med. 2017;377:454–464.
   PubMed Web of Science ®Google Scholar
• Perl AE, Altman JK, Cortes J, et al. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicenter, first-in-human, open-label, phase 1-2 study. Lancet Oncol. 2017;18:1061–1075.
   PubMed Web of Science ®Google Scholar
• Stein EM, DiNardo CD, Fathi AT, et al. Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib. Blood. 2019;133:676–687.
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Stein EM, de Botton S, et al. Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML. N Engl J Med. 2018;378:2386–2398.
   PubMed Web of Science ®Google Scholar
• Castaigne S, Pautas C, Terré C, et al. Effects of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukemia (ALFA-0701): a randomized, open-label, phase 3 study. Lancet. 2012;379:1508–1516.
   PubMed Web of Science ®Google Scholar
• Wei AH, Strickland SA Jr, Hou JZ, et al. Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase 1b/2 study. J Clin Oncol. 2019;37:1277–1284.
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Pratz K, Pullarkat V, et al. Venetoclax combined with decitabine or azacitidine in treatment-naïve, elderly patients with acute myeloid leukemia. Blood. 2019;133:7–17.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Heidel FH, Hellmann A, et al. Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. Leukemia. 2019;33:379–389.
   PubMed Web of Science ®Google Scholar
• Nusslein-Volhard C, Wieschaus E. Mutations affecting segment number and polarity in Drosophila. Nature. 1980;287:795–801.
   PubMed Web of Science ®Google Scholar
• Amakye D, Jagani Z, Dorsch M. Unraveling the therapeutic potential of the hedgehog pathway in cancer. Nat Med. 2013;19:1410–1422.
   PubMed Web of Science ®Google Scholar
• Gao J, Graves S, Koch U. Hedgehog signaling is dispensable for adult hematopoietic stem cell function. Cell Stem Cell. 2009;4:548–558.
   PubMed Web of Science ®Google Scholar
• Kobune M, Iyama S, Kikuchi S, et al. Stromal cells expressing hedgehog-interacting protein regulate the proliferation of myeloid neoplasms. Blood Cancer J. 2012;2:e87.
   PubMed Web of Science ®Google Scholar
• Xu F, Yang R, Wu L, et al. Overexpression of BMI1 confers clonal cells resistance to apoptosis and contributes to adverse prognosis in myelodysplastic syndrome. Cancer Lett. 2012;317:33–40.
   PubMed Web of Science ®Google Scholar
• Xavier JM, Santos Duarte AS, Pericole FV, et al. Hedgehog pathway is deregulated in myelodysplastic syndrome progenitor bone marrow cells. Blood. 2013;122(suppl.1):1533.
   PubMedGoogle Scholar
• Li X, Chen F, Zhu Q, et al. Gli/Pl3K/AKT/NF-κB pathway mediates resistance to radiation and is a target for reversion of responses in refractory acute myeloid leukemia cells. Oncotarget. 2016;7:33004–33015.
   PubMedGoogle Scholar
• Wellbrock J, Latuske E, Kohler J, et al. Expression of Hedgehog pathway mediator GLI represents a negative prognostic marker in human acute myeloid leukemia and its inhibition exerts antileukemic effects. Clin Cancer Res. 2015;21:2388–2398.
   PubMed Web of Science ®Google Scholar
• Munchhof MJ, Li Q, Shavnya A, et al. Discovery of PF-04449913, a potent and orally bioavailable inhibitor of smoothened. ACS Med Chem Lett. 2012;3:106–111.
   PubMed Web of Science ®Google Scholar
• Shaik MN, LaBadie RR, Rudin D, et al. Evaluation of the effect of food and ketoconazole on the pharmacokinetics of the smoothened inhibitor PF-04449913 in healthy volunteers. Cancer Chemother Pharmacol. 2014;74:411–418.
   PubMed Web of Science ®Google Scholar
• Lam JL, Vaz A, Hee B, et al. Metabolism, excretion and pharmacokinetics of [14C]glasdegib (PF-04449913) in healthy volunteers following oral administration. Xenobiotica. 2017;47:1–13.
   PubMed Web of Science ®Google Scholar
• Giri N, Lam LH, LaBadie RR, et al. Evaluation of the effect of new formulation, food, or a proton pump inhibitor on the relative bioavailability of the smoothened inhibitor glasdegib (PF-04449913) in healthy volunteers. Cancer Chemother Pharmacol. 2017;80:1249–1260.
   PubMed Web of Science ®Google Scholar
• Shaik N, Hee B, Wei H, et al. Evaluation of the effect of rifampin on the pharmacokinetics of the smoothened inhibitor glasdegib in healthy volunteers. Br J Clin Pharmacol. 2018;84:1346–1353.
   PubMed Web of Science ®Google Scholar
• Shaik N, Hee B, Wei H, et al. Evaluation of the effects of formulation, food, or a proton-pump inhibitor on the pharmacokinetics of glasdegib (PF-04449913) in healthy volunteers: a randomized phase I study. Cancer Chemother Pharmacol. 2019;83:463–472.
   PubMed Web of Science ®Google Scholar
• Shaik N, Hee B, Liang Y, et al. Absolute oral bioavailability of glasdegib (PF-04449913), a smoothened inhibitor, in randomized healthy volunteers. Clin Pharmacol Drug Dev. 2019;8:895–902. Epub ahead of print.
   Web of Science ®Google Scholar
• Minami Y, Hayakawa F, Kiyoi H, et al. Treatment with hedgehog inhibitor, PF-04449913, attenuates leukemia-initiation potential in acute myeloid leukemia cells. Blood. 2013;122:1649.
   PubMed Web of Science ®Google Scholar
• Skoda AM, Simovic D, Karin V, et al. The role of the hedgehog signaling pathway in cancer: a comprehensive review. Bosn J Basic Med Sci. 2018;1:18–20.
   Google Scholar
• Smith AG, Macleod KF. Autophagy, cancer stem cells and drug resistance. J Pathol. 2019;247:708–718.
   PubMed Web of Science ®Google Scholar
• Fukushima N, Minami Y, Kakiuchi S, et al. Small-molecule Hedgehog inhibitor attenuates the leukemia-initiation potential of acute myeloid leukemia cells. Cancer Sci. 2016;107:1422–1429.
   PubMed Web of Science ®Google Scholar
• Sadarangani A, Pineda G, Lennon KM, et al. GLI2 inhibition abrogates human leukemia stem cell dormancy. J Transl Med. 2015;13:98.
   PubMed Web of Science ®Google Scholar
• Zou J, Zhou Z, Wan L, et al. Targeting the Sonic Hedgehog-Gli1 pathway as a potential new therapeutic strategy for myelodysplastic syndromes. PLoS One. 2015;10:e0136843.
   PubMed Web of Science ®Google Scholar
• Tibes R, Al-Kali A, Oliver G, et al. The Hedgehog pathway as targetable vulnerability with 5-azacytidine in myelodysplastic syndrome and acute myeloid leukemia. J Hematol Oncol. 2015;8:114.
   PubMed Web of Science ®Google Scholar
• Minami Y, Minami H, Miyamoto T, et al. Phase I study of glasdegib (PF-04449913), an oral smoothened inhibitor, in Japanese patients with select hematologic malignancies. Cancer Sci. 2017;108:1628–1633.
   PubMed Web of Science ®Google Scholar
• Savona MR, Pollya DA, Stock W, et al. Phase Ib study of glasdegib, a Hedgehog pathway inhibitor, in combination with standard chemotherapy in patients with AML or high-risk MDS. Clin Cancer Res. 2018;24:2294–2303.
   PubMed Web of Science ®Google Scholar
• Martinelli G, Oehler VG, Papayannidis C, et al. Treatment with PF-04449913, an oral smoothened antagonist, in patients with myeloid malignancies: a phase I safety and pharmacokinetics study. Lancet Haematol. 2015;2:e339–e346.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Smith BD, Wang ES, et al. Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: phase 2 study results. Am J Hematol. 2018;93:1301–1310.
   PubMed Web of Science ®Google Scholar
• Lin S, Shaik MN, Chan G, et al. Population pharmacokinetic/pharmacodynamics evaluation of the relationship between glasdegib treatment/exposure and overall survival in AML patients. Blood. 2018;132(suppl.1):1450.
   Google Scholar
• Westley T, Forsythe A, Bell TJ, et al. Clinical responses of glasdegib plus low-dose AraC, azacitidine, and decitabine among acute myeloid leukemia (AML) patients ineligible to receive intensive chemotherapy: comparative effectiveness using indirect treatment comparison (ITC) methods. Blood. 2018;132(suppl.1):2709.
   Google Scholar
• Forsythe A, Arondekar B, Tremblay G, et al. Systematic literature review and indirect comparison of glasdegib plus low dose Ara-C versus a Hypomethylating agent for acute myeloid leukemia patients ineligible for intensive chemotherapy. Haematologica. 2017;102(Suppl.2):E925.
   Google Scholar
• Fenaux P, Mufti GJ, Hellström-Lindberg E, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol. 2010;28:562–569.
   PubMed Web of Science ®Google Scholar
• Dombret H, Seymour JF, Butrym A, et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with > 30% blasts. Blood. 2015;126:291–299.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Thomas XG, Dmoszynska A, et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol. 2012;30:2670–2677.
   PubMed Web of Science ®Google Scholar
• Wagner AJ, Messersmith WA, Shaik MN, et al. A phase I study of PF-04449913, an oral Hedgehog inhibitor, in patients with advanced solid tumors. Clin Cancer Res. 2015;21:1044–1051.
   PubMed Web of Science ®Google Scholar
• Low JA, de Sauvage FJ. Clinical experience with Hedgehog pathway inhibitors. J Clin Oncol. 2010;28:5321–5326.
   PubMed Web of Science ®Google Scholar
• Gerds AT, Tauchi T, Ritchie E, et al. Phase 1/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinib. Leuk Res. 2019;79:38–44.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Papayannidis C, Jamieson C, et al. Glasdegib in addition to intensive or non-intensive chemotherapy in patients with acute myeloid leukemia: safety analysis of glasdegib ‘on target’ adverse events. Blood. 2018;132(suppl.1):2732.
   Google Scholar
• Norsworthy KJ, By K, Subramaniam S, et al. FDA approval summary: glasdegib for newly diagnosed acute myeloid leukemia. Clin Cancer Res. 2019;25:6021–6025. CCR-19-0365 [ Epub ahead of print. .
   Web of Science ®Google Scholar
• Rao AV, Valk PJ, Metzeler KH, et al. Age-specific differences in oncogenic pathway dysregulation and anthracycline sensitivity in patients with acute myeloid leukemia. J Clin Oncol. 2009;27:5580–5586.
   PubMed Web of Science ®Google Scholar
• Migden MR, Guminski A, Gutzmer R, et al. Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicenter, randomized, double-blind phase 2 trial. Lancet Oncol. 2015;16:716–728.
   PubMed Web of Science ®Google Scholar
• Sekulic A, Migden MR, Oro AE, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012;366:2171–2179.
   PubMed Web of Science ®Google Scholar
• Lauressergues E, Heusler P, Lestienne F, et al. Pharmacological evaluation of a series of smoothened antagonists in signaling pathways and after topical application in a depilated mouse model. Pharmacol Res Perspect. 2016;4:e00214.
   PubMed Web of Science ®Google Scholar
• Gupta S, Takebe N, LoRusso P. Targeting the hedgehog pathway in cancer. Ther Adv Med Oncol. 2010;2:237–250.
   PubMedGoogle Scholar
• Goel V, Hurh E, Stein A, et al. Population pharmacokinetics of sonidegib (LDE225), an oral inhibitor of hedgehog pathway signaling, in healthy subjects and in patients with advance solid tumors. Cancer Chemother Pharmacol. 2016;77:745–755.
   PubMed Web of Science ®Google Scholar
• Jackson-Fisher A, McMahon MJ, Lam J, et al. PF-04449913, a small molecule inhibitor of the hedgehog signaling pathway, is effective in inhibiting tumor growth in preclinical models. Clin Cancer Res. 2011;71:4504.
   Google Scholar
• Gibson CJ, Steensma DP. New insights from studies of clonal hematopoiesis. Clin Cancer Res. 2018;24:4633–4642.
   PubMed Web of Science ®Google Scholar
• Chan SM, Majeti R. Role of DNMT3A, TET2, and IDH1/2 mutations in pre-leukemic stem cells in acute myeloid leukemia. Int J Hematol. 2013;98:648–657.
   PubMed Web of Science ®Google Scholar
• Ng SW, Mitchell A, Kennedy JA, et al. A17-gene stemness score for rapid determination of risk in acute leukaemia. Nature. 2016;540:433–437.
   PubMed Web of Science ®Google Scholar